Posted by Michael Wonder on 03 Nov 2021
Opdivo receives two new Health Canada approvals
2 November 2021 - Today Bristol Myers Squibb Canada announces two recent Health Canada approvals for Opdivo (nivolumab).
On 28 October 2021, Health Canada approved Opdivo for the treatment of HER2 negative advanced or metastatic gastric cancer, gastro-esophageal junction cancer or oesophageal adenocarcinoma, in combination with fluoropyrimidine and platinum- containing chemotherapy.
